SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on April 24, 2003; DOI 10.1182/blood-2003-02-0440. This Article Full Text (PDF) All Versions of this Article: 2003-02-0440v1 102/5/1595    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Lemoli, R. M Articles by Baccarani, M. Search for Related Content PubMed PubMed Citation Articles by Lemoli, R. M Articles by Baccarani, M. Social Bookmarking                   What's this? Submitted February 10, 2003 Accepted April 18, 2003 Autologous transplantation of granulocyte colony-stimulating factor-primed bone marrow is effective to support myeloablative chemotherapy in patients with hematological malignancies and poor peripheral blood stem cell mobilization Roberto M Lemoli*, Antonio de Vivo, Daniela Damiani, Alessandro Isidori, Monica Tani, Alessandro Bonini, Claudia Cellini, Antonio Curti, Luigi Gugliotta, Giuseppe Visani, Renato Fanin, and Michele Baccarani Institute of Hematology and Medical Oncology, University of Bologna, Bologna, Italy Hematology Service, S.Maria Nuova Hospital, Reggio Emilia, Italy Hematology Service, S.Salvatore Hospital, Pesaro, Italy Chair of Hematology, University Hospital, Udine, Italy * Corresponding author; email: rmlemoli{at}med.unibo.it. We assessed the hematopoietic recovery and transplant-related mortality (TRM) of patients who had failed peripheral blood stem cell mobilization and subsequently received high-dose chemotherapy supported by G-CSF-primed bone marrow (BM). Eighty-six heavily pretreated consecutive patients with acute leukemia (= 21), refractory/relapsed non-Hodgkin[[rad]]s lymphoma (=41) and Hodgkin[[rad]]s disease (=17), and multiple myeloma (=7) were studied. Seventy-eight patients showed insufficient mobilization of CD34+ cells (<10 cells/µL) whereas 8 patients collected < 1x106 CD34+ cells/Kg. BM was primed in vivo for 3 days with 15-16 µg/Kg of subcutaneous G-CSF. Median numbers of nucleated cells, CFU-C and CD34+ cells/Kg harvested were 3.5x108, 3.72x104 and 0.82x106, respectively. Following myeloablative chemotherapy, median times to achieve a granulocyte count >0.5x109/L and an unsupported platelet count >20 and 50x109/L were 13 (range; 8-24), 15 (12-75) and 22 (12-180) days for lymphoma/myeloma patients and 23 (13-53), 52 (40-120) and 90 (46-207) days for leukemia patients. Median times to hospital discharge after transplant were 17 (12-40) and 27 (14-39) days for lymphoma/myeloma and acute leukemia patients, respectively. TRM was 4.6% whereas 15 patients died of disease. G-CSF-primed BM induces effective multilineage hematopoietic recovery after high-dose chemotherapy and can be safely used in patients with poor stem cell mobilization. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: R. M. Lemoli and A. D'Addio Hematopoietic stem cell mobilization Haematologica, March 1, 2008; 93(3): 321 - 324. [Full Text] [PDF] S. Fukuda, H. Bian, A. G. King, and L. M. Pelus The chemokine GRO{beta} mobilizes early hematopoietic stem cells characterized by enhanced homing and engraftment Blood, August 1, 2007; 110(3): 860 - 869. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020